mProX™ Human FGFR2 Stable Cell Line

Product Information

Target Protein

FGFR2

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

NSCLC; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Reproductive Research

Related Diseases

Pfeiffer Syndrome and Crouzon Syndrome. Among its related pathways are Apoptotic Pathways in Synovial Fibroblasts and GPCR Pathway

Gene ID

2263

UniProt ID

P21802

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Instructions for producing a protein known as fibroblast growth factor receptor 2 are found in the FGFR2 gene. The FGFR2 protein crosses the outer membrane that envelops cells, with one end of the protein staying within the cell and the other end protruding from its outside. Growth factors bind to the FGFR2 protein, and the receptor sets off a sequence of internal chemical events that direct the cell to alter in specific ways. Particularly during the period of development just before birth, known as embryonic development, the FGFR2 protein is crucial for bone growth. The regular process of breaking down old bone and creating new bone to replace it is known as bone remodeling, and the protein plays a role in this process as well. The customized FGFR2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Kimberly

This FGFR2 cell line is highly selective. Its performance has been outstanding, demonstrating reliable and consistent binding. Sep 19 2021

chat Verified Customer

chat Michael

This FGFR2 cell line can be applied well according to experimental needs. Jan 03 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 FGFR2 -amplified cell lines are sensitive to FGFR2 silencing and FGFR inhibition.

Western blot of 15 breast cancer cell lines showing that FGFR2 protein is overexpressed in MFM223. FGFR2 was commonly seen as a doublet, which represents various extracellular domain glycosylation statuses.

Ref: Turner, Nicholas, et al. "Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets." Oncogene 29.14 (2010): 2013-2023.

Pubmed: 20101236

DOI: 10.1038/onc.2009.489

Research Highlights

Numerous cancer types have somatic hotspot mutations, structural amplifications and fusions that impact fibroblast growth factor receptor 2 (encoded by FGFR2).
Zingg, Daniel, et al. "Truncated FGFR2 is a clinically actionable oncogene in multiple cancers." Nature 608.7923 (2022): 609-617.
Pubmed: 35948633 DOI: 10.1038/s41586-022-05066-5

The use of futibatinib, a covalent FGFR inhibitor, produced demonstrable clinical benefit in previously treated patients with FGFR2 fusion or rearrangement-positive intrahepatic cholangiocarcinoma.
Goyal, Lipika, et al. "Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma." New England Journal of Medicine 388.3 (2023): 228-239.
Pubmed: 36652354 DOI: 10.1056/NEJMoa2206834